Short‐term safety and efficacy of left atrial appendage closure with the WATCHMAN device in patients with small left atrial appendage ostia
Left atrial appendage (LAA) closure with the WATCHMAN (Boston Scientific, Natick, MA, USA) device is a safe and effective alternative to long‐term anticoagulation with warfarin, and reduces the risk of thromboembolism (TE) from the LAA in patients with nonvalvular atrial fibrillation (AF, 1–5). LAA closure with the WATCHMAN device is indicated for patients with a maximal LAA ostial width between 17 and 31 mm, as determined by a screening transesophageal echocardiogram (TEE). Data regarding the safety and efficacy of LAA closure with the WATCHMAN device in patients with a maximal LAA ostial width < 17 mm are not available. The goal of this study was to determine the acute and short‐term safety and efficacy outcomes in patients undergoing LAA closure with the WATCHMAN device who have small LAA ostia, < 17 mm.